false000170429200017042922024-06-112024-06-110001704292dei:AdrMember2024-06-112024-06-110001704292us-gaap:CommonStockMember2024-06-112024-06-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 11, 2024
________________________
ZAI LAB LIMITED
(Exact name of registrant as specified in its charter)
________________________
Cayman Islands001-3820598-1144595
(State or other jurisdiction of
incorporation or organization)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
4560 Jinke Road
Bldg. 1, Fourth Floor, Pudong
Shanghai, China
201210
314 Main Street
4th Floor, Suite 100
Cambridge, MA, USA		02142
(Address of principal executive offices)(Zip Code)
+86 21 6163 2588
+1 857 706 2604
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per shareZLABThe Nasdaq Global Market
Ordinary Shares, par value $0.000006 per share*9688The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 11, 2024, Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024. There were no disagreements between Dr. Reinhart and the Company relating to the Company’s operations, policies, or practices that resulted in his decision to retire. Dr. Reinhart will continue to serve as a senior advisor to the Company.

Item 7.01 Regulation FD Disclosure.
On June 11, 2024, the Company also announced that Dr. Rafael Amado, President, Head of Global Oncology Research and Development, will be expanding his role to President, Head of Global Research and Development, effective upon Dr. Reinhart’s retirement on June 30, 2024.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
104The cover page of this Current Report on Form 8-K is formatted in Inline XBRL


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZAI LAB LIMITED
By:/s/ F. Ty Edmondson
F. Ty Edmondson
Chief Legal Officer and Corporate Secretary
Date: June 11, 2024


Exhibit 99.1
zailablogo.jpg


Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases;
Dr. Rafael Amado to be Appointed President, Head of Global R&D

SHANGHAI and CAMBRIDGE, Mass., June 11, 2024 – Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company’s Global R&D upon Dr. Reinhart’s retirement.
“Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in need around the world,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “Harald joined Zai Lab 10 years ago bringing his experience in infectious diseases and later significantly expanding the Company’s capabilities in autoimmune and neuroscience. ”
Dr. Du continued, “It has been a pleasure to work alongside Harald, and we wish him well in his retirement. He has built a strong team and solid foundation that will continue to grow under Rafael’s leadership.”
Dr. Reinhart said, “It’s been a great honor to work with such a talented and dedicated team. I’m very proud of our accomplishments, delivering and developing novel treatments in NSAiID. I look forward to Zai’s continued success.”
As Head of Global R&D, Dr. Amado will continue to advance Zai Lab’s existing and future pipelines across all therapy areas. He has held senior positions and advisory roles in pharmaceutical and biotechnology companies where he was responsible for the discovery and development of a variety of products, across modalities and therapeutic areas.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements about future expectations, plans, and prospects, including, without limitation, statements relating to the prospects and plans for Zai Lab’s management, operations, and growth potential. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business
1

in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC’s website at www.sec.gov.

For more information, please contact:
Investor Relations:
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com
Media:
Shaun Maccoun / Xiaoyu Chen
+1 (857) 270-8854 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com


image_0.jpg
Zai Lab Limited


2
v3.24.1.1.u2
Cover
Jun. 11, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Jun. 11, 2024
Entity Registrant Name ZAI LAB LIMITED
Entity Incorporation, State or Country Code E9
Entity File Number 001-38205
Entity Tax Identification Number 98-1144595
Entity Address, Address Line One 4560 Jinke Road
Entity Address, Address Line Two Bldg. 1, Fourth Floor, Pudong
Entity Address, City or Town Shanghai
Entity Address, Country CN
Entity Address, Postal Zip Code 201210
City Area Code 86 21
Local Phone Number 6163 2588
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001704292
ADR  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share
Trading Symbol ZLAB
Security Exchange Name NASDAQ
Common Stock  
Document Information [Line Items]  
Title of 12(b) Security Ordinary Shares, par value $0.000006 per share*
Trading Symbol 9688
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Zai Lab Charts.
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Zai Lab Charts.